Alterations in p53-specific T cells and other lymphocyte subsets in breast cancer patients during vaccination with p53-peptide loaded dendritic cells and low-dose interleukin-2
/in Breast Cancer, Dendritic Cells, International Publications /von 2008-07-09 / Vaccine 2008 Aug;26(36):4716-24Fusions of dendritic cells with breast carcinoma stimulate the expansion of regulatory T cells while concomitant exposure to IL-12, CpG oligodeoxynucleotides, and anti-CD3/CD28 promotes the expansion of activated tumor reactive cells
/in Breast Cancer, International Publications /von 2008-07-01 / J. Immunol. 2008 Jul;181(1):808-21Ex vivo recovery and activation of dysfunctional, anergic, monocyte-derived dendritic cells from patients with operable breast cancer: critical role of IFN-alpha
/in Breast Cancer, Dendritic Cells, International Publications /von 2008-06-27 / BMC Immunol. 2008 Jun;9:32Cancer immunotherapy using in vitro genetically modified targeted dendritic cells
/in Breast Cancer, International Publications /von 2008-05-15 / Cancer Res. 2008 May;68(10):3854-62Reengineering dendritic cell-based anti-cancer vaccines
/in Breast Cancer, International Publications /von 2008-04-01 / Immunol. Rev. 2008 Apr;222:256-76The importance of schedule in whole body thermochemotherapy
/in Breast Cancer, Hyperthermia, International Publications /von 2008-03-01 / Int J Hyperthermia 2008 Mar;24(2):171-81Immunisation with ’naïve‘ syngeneic dendritic cells protects mice from tumour challenge
/in Breast Cancer, International Publications /von 2008-02-05 / Br. J. Cancer 2008 Feb;98(4):784-91[Dendritic cells elicit cellular immune response by targeting to capture breast cancer cells]
/in Breast Cancer, International Publications /von 2008-02-01 / Zhonghua Zhong Liu Za Zhi 2008 Feb;30(2):107-11Characteristics of hybrid cells obtained by dendritic cell/tumour cell fusion in a T-47D breast cancer cell line model indicate their potential as anti-tumour vaccines
/in Breast Cancer, International Publications /von 2007-12-01 / Int. J. Oncol. 2007 Dec;31(6):1357-65
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de